ALLMedicine™ Acute Angioedema Center
Research & Reviews 22 results
Postgraduate Medicine; Tachdjian R, Johnston DT
Jun 18th, 2021 - A clinical vignette illustrates a typical presentation of a patient seeking help for acute angioedema. Despite the risks of SARS-CoV-2 (COVID-19) exposure, it is critical to evaluate patients with acute angioedema in person, because there is alway...
Pediatric Emergency Care; García Sánchez P, Plata Gallardo M et. al.
May 20th, 2021 - C1 inhibitor deficiency is a rare, potentially life-threatening syndrome. Acute attacks of angioedema may occur at any time, so the emergency department (ED) constitutes an indispensable component of its care. To describe the reasons for consultat...
Aesthetic Surgery Journal; Berenguer B, García T et. al.
Apr 1st, 2021 - Life-Threatening Acute Angioedema, a Rare Complication After Secondary Blepharoplasty.|2021|Berenguer B,García T,San Basilio M,|
BMC Pediatrics; Syue YJ, Li CJ et. al.
Nov 12th, 2019 - The initial episode of angioedema in children can be potential life-threatening due to the lack of prompt identification and treatment. We aimed to analyze the factors predicting the severity and outcomes of the first attack of acute angioedema in...
Allergy and Asthma Proceedings; Schuler CF, Pedersen EA et. al.
Sep 14th, 2019 - Angioedema is a potentially life-threatening swelling condition that can occur either in isolation or in the context of other syndromes, e.g., anaphylaxis. Angioedema is typically asymmetric, lasts for hours to days, is not gravity dependent, and ...
Clinicaltrials.gov 3 results
Apr 16th, 2019 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
Oct 9th, 2018 - This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
Aug 7th, 2015 - HAE is characterized by recurrent localized angioedema caused by uncontrolled activation of the complement and contact systems due to a congenital deficiency of functional C1 inhibitor. rhC1INH has been developed to offer a more widely available t...
News 2 results
Jul 17th, 2014 - Ruconest, an injectable human recombinant C1-esterase inhibitor, has been approved by the Food and Drug Administration for treating acute angioedema attacks in adults and adolescents with hereditary angioedema. Ruconest is the first recombinant C1.
Family Practice News;
Apr 8th, 2011 - Because many of the adverse events that were most commonly reported are associated with hereditary angioedema, "we could not separate whether this was due to drug effect or due to the attack," Dr. Lumry said.